Tarceva Monotherapy Shows Survival Benefit, Differentiates Oncologic From Iressa – Genentech

Genentech/OSI project summer filing and Q1 2005 launch following positive findings from a pivotal monotherapy study. The refractory NSCLC study is slated for presentation at the American Society of Clinical Oncology meeting in June.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet